Introduction: Ischaemic heart disease (IHD) ranks among the five leading causes of death in Spain, with a mortality rate of around 75 deaths per 100,000 population. Currently, the principal treatment for de novo coronary lesions is percutaneous coronary intervention (PCI), using metal or drugeluting stents. In 2011, the mean PCI rate in Spain was 1373/106 population. Recently, a new generation of bioabsorbable stents (Bioabsorbable Vascular Scaffold, BVS) has emerged as a complement or alternative to metal or drug-eluting stents, aimed at providing support for the vessel for at least 2 years (period of reabsorption) without the potential long-term limitations entailed by the existence of a permanent metal structure.

 Objectives: To ascertain the safety and efficacy of bioabsorbable everolimuseluting coronary stents for treating IHD due to de novo lesions in native coronary arteries.

 Methods:A systematic review of the literature was conducted in the
following databases: Centre for Reviews and Dissemination (CRD); Medline (PubMed); EMBASE (Ovid); Institute for Scientific Information Web of Science (Web of Knowledge, WoK); and ClinicalTrial.gov. The strategy was implemented in October 2012, with monthly updates being conducted until the document's date of publication, in order to retrieve recently published studies. Two reviewers, acting independently, selected the papers on the basis of pre-established inclusion/exclusion criteria. The data were then summarised in evidence tables, and the methodological quality of the studies was separately assessed by two researchers using the scale drawn up by the Scottish Intercollegiate Guidelines Network.

Results, discussion and conclussion:Results, discussion and conclussion: See pdf below.